ANTX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 birž. 2024 @ 23:00):
Our systems believe the stock currently is overvalued by -0.42% compare to its pairs and should correct downwards.

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases...

Stats
Šios dienos apimtis	111 577
Vidutinė apimtis	190 335
Rinkos kapitalizacija	64.13M
EPS	$-0.560 ( Q1 \| 2024-05-14 )
Kita pelno data	( $-0.630 ) 2024-08-08
Last Dividend	$0.656 ( 2018-01-11 )
Next Dividend	$0 ( N/A )
P/E	-0.860 (Sector) 49.64 (Industry) 46.06
ATR14	$0.00900 (0.42%)

ADCT 12.46%

AMAM 0.07%

ANRO 0.56%

ANTX -3.59%

BHVN -1.08%

BWV -6.97%

DNA 8.12%

DNA-WT -0.35%

DYN -0.37%

GLS 0.00%

KDMN 0.00%

MYOV -0.04%

NUVB -3.95%

NUVB-WT -0.18%

NVO -1.21%

PRME -3.56%

RCUS 0.40%

SQZ 61.11%

TOVX -2.80%

ZYME 1.19%

Insider Trading

Date	Person	Action	Amount	type
2024-06-19	Readnour Robin Shane	Buy	64 503	Stock Option (Right to Buy)
2024-06-19	Marks Gilbert Lynn	Buy	64 503	Stock Option (Right to Buy)
2024-06-19	Fitzpatrick Margaret M	Buy	64 503	Stock Option (Right to Buy)
2024-06-19	Aziz Kabeer	Buy	64 503	Stock Option (Right to Buy)
2024-06-19	Zakrzewski Joseph S	Buy	64 503	Stock Option (Right to Buy)

INSIDER POWER
71.15
Last 100 transactions
Buy: 3 873 538 \| Sell: 620 226

Koreliacija (AI algo v.1.1b): Overvalued: -0.42% $2.15 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.07 (neutral)

Trumpas: 0.02 (neutral)

Signal:(52.965) Neutral

Anthem Inc. Corporate Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
EXPR	0.959
KREF	0.958
NYCB	0.954
CMTG	0.933
MLNK	0.929
BERY	0.92
MKFG-WT	0.92
ACRE	0.919
HPP	0.913
NYCB-PA	0.912

10 Labiausiai neigiamai susiję koreliacijos
AMBP	-0.964
LLY	-0.948
POST	-0.939
PH	-0.932
XPO	-0.927
APO	-0.926
ET-PE	-0.922
ADCT	-0.921
ETJ	-0.915
IR	-0.913

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Anthem Inc. Corporate Koreliacija - Valiuta/Žaliavos

0.26
( neutral )

-0.71
( moderate negative )

0.00
( neutral )

0.19
( neutral )

0.15
( neutral )

0.39
( neutral )

Anthem Inc. Corporate Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-2.74

FY	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-2.74

FY	2022
Pajamos:	$0
Bruto pelnas:	$-77 000.00 (0.00 %)
EPS:	$-2.14

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.534

Financial Reports:

No articles found.

Anthem Inc. Corporate Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Anthem Inc. Corporate Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.576	2015-07-13
Last Dividend	$0.656	2018-01-11
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$7.14	--
Avg. Dividend % Per Year	0.00%	--
Score	1.61	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-09-23)

$0 Estimate 0.00 %

Dividend Stability

0.06 Very Bad

Dividend Score

1.61

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
11 Jan 2018	$0.656	30 Nov -0001	30 Nov -0001	30 Nov -0001
12 Oct 2017	$0.656	30 Nov -0001	30 Nov -0001	30 Nov -0001
12 Jul 2017	$0.656	30 Nov -0001	30 Nov -0001	30 Nov -0001
11 Apr 2017	$0.656	30 Nov -0001	30 Nov -0001	30 Nov -0001
11 Jan 2017	$0.656	30 Nov -0001	30 Nov -0001	30 Nov -0001
12 Oct 2016	$0.656	30 Nov -0001	30 Nov -0001	30 Nov -0001
13 Jul 2016	$0.656	30 Nov -0001	30 Nov -0001	30 Nov -0001
13 Apr 2016	$0.656	30 Nov -0001	30 Nov -0001	30 Nov -0001
13 Jan 2016	$0.656	30 Nov -0001	30 Nov -0001	30 Nov -0001
13 Oct 2015	$0.656	30 Nov -0001	30 Nov -0001	30 Nov -0001
13 Jul 2015	$0.576	30 Nov -0001	30 Nov -0001	30 Nov -0001

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
ECC	Dividend Diamond	2024-07-11	Monthly	11	14.91%	9.72
BRW	Dividend Diamond	2024-06-11	Monthly	33	9.41%	9.26
VVR	Dividend Diamond	2024-06-18	Monthly	27	8.85%	9.19
FCT	Dividend Diamond	2024-06-03	Monthly	21	8.33%	9.14
PHK	Dividend Diamond	2024-06-13	Monthly	22	9.07%	9.13
SBR	Dividend Diamond	2024-06-17	Monthly	38	9.57%	9.10
XFLT	Dividend Diamond	2024-06-17	Monthly	8	10.49%	9.09
SRV	Dividend Royal	2024-07-16	Monthly	18	10.61%	9.04
FAM	Dividend Royal	2024-06-03	Monthly	20	8.07%	8.98
RA	Dividend Diamond	2024-06-11	Monthly	9	10.10%	8.93

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-825.33	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.544	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.572	1.500	-7.46	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	10.91	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	10.76	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.32	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-100.41	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.992	2.00	-0.664	-1.328	[0 - 30]
freeCashFlowPerShareTTM	-1.992	2.00	-0.996	-1.992	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.238	1.000	9.38	9.38	[0.2 - 0.8]
operatingProfitMarginTTM	-898.65	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.000660	0.800	-3.33	-2.66	[0.5 - 2]
Total Score				-2.57

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.969	1.000	-0.199	0	[1 - 100]
returnOnEquityTTM	-0.572	2.50	-4.80	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.992	2.00	-0.664	-1.992	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.992	2.00	-0.664	-1.328	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.00969	1.500	-3.40	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-741.06	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.80

Anthem Inc. Corporate Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Anthem Inc. Corporate

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.